Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.54 |
| ▸ | RXRB | P28702 | 1/20 | 0.54 |
| ▸ | RXRG | P48443 | 1/20 | 0.54 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PDE1A | P54750 | 1/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19915968 | 0.88 | RXRA (0.45) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL12272136 | 0.83 | RXRA (0.55) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL30811759 | 0.82 | RXRA (0.47) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL25413737 | 0.81 | RXRA (0.44) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL19915966 | 0.80 | IDO1 (0.54) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL29561359 | 0.80 | IDO1 (0.54) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL21196196 | 0.78 | CYP4F2 (0.45) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL30950246 | 0.78 | CYP4F2 (0.45) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL17731741 | 0.78 | RXRA (0.42) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL29561854 | 0.78 | RXRA (0.42) | RXRARXRBRXRGCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109689652-B | Fused heterocyclic derivative, preparation method and medical application thereof | 北京诺诚健华医药科技有限公司 | 2022-04-26 | — | — | CN | disclosed |
| US-11046682-B2 | Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-06-29 | — | — | US | disclosed |
| US-11046682-B2 | Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-06-29 | — | — | US | disclosed |
| EP-3505517-A1 | FUSED HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2019-07-03 | — | — | EP | disclosed |
| EP-3505517-A1 | FUSED HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2019-07-03 | — | — | EP | disclosed |
| US-20190185472-A1 | FUSED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
| US-20190185472-A1 | FUSED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
| WO-2018036414-A1 | FUSED HETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 北京诺诚健华医药科技有限公司 | 2018-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185472-A1 | FUSED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION METHODS THEREOF AND MEDICAL USES THEREOF | IDO1, IDO2, INMT | RXRA 2889/4885RXRB 2860/4885RXRG 2838/4885 |
| US-11046682-B2 | Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof | IDO1, IDO2, INMT | RXRA 2889/4885RXRB 2860/4885RXRG 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.